Actively Recruiting
Phase IIIb Study Evaluating Safety and Efficacy of Out-of-Specification Tisagenlecleucel in Patients with RelapsedRefractory B-cell Acute Lymphoblastic Leukemia and Large B-cell Lymphoma
Led by Novartis Pharmaceuticals · Updated on 2026-09-15
200
Participants Needed
55
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety of tisagenlecleucel that does not meet the usual commercial release specifications in patients with relapsed or refractory B-cell acute lymphoblastic leukemia pALL and large B-cell lymphoma LBCL, including diffuse large B-cell lymphoma and other related lymphomas. This Phase IIIb, open-label study focuses on patients treated within approved label indications, particularly in Japan. The study aims to assess safety and, in part one, also key efficacy measures of the investigational CTL019 therapy. Participants receive a single intravenous infusion of CTL019, a biological therapy consisting of CAR-positive viable T cells. The study includes three patient groups pediatric or young adults with pALL, adults with LBCL, and adults with non-Hodgkins lymphoma NHL consistent with label indications. After infusion, patients in part one are monitored for safety and efficacy for up to three months, while those in part two have safety followed for one day. During the study, participants are closely observed for adverse events and treatment responses. Safety assessments occur from screening through the follow-up periods. The main outcome is the percentage of participants experiencing adverse events. Additionally, for part one, remission and response rates are measured. The trial lasts until March 2027, with comprehensive monitoring to ensure participant safety and evaluate treatment impact.
CONDITIONS
Brief Title
Study of Out of Specification for Tisagenlecleucel
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here